10/11/2016
`Page 1
`
`
`
`Field
`Clinical Pharmacy
`
`
`
`Pharmaceutics
`
`
`Biochemical
`Pharmacology
`
`
`
`Postdoctoral 1979-1980
`Fellow
`
`
`
`
`
`
`
`
`
`RESEARCH INTERESTS
`
`Development of effective treatments of solid tumors has been my career goal. Our group has thus far
`taken two of our discoveries through clinical evaluation (including a phase III study that yielded
`positive findings). My work is typically in the interface between diverse disciplines, with the goal of
`translating laboratory findings to survival-extending cancer treatments. My research goal for the next
`five years is to continue the development of several discoveries from my lab at Optimum
`Therapeutics, a biotech company I co-founded in 2003 and where I currently serve as Chief
`Scientific Officer. On a broader scale, my goal is to develop a new field of studies, Oncometrics,
`which I define as using computation and modeling to improve the success rate of clinical cancer drug
`development (currently at <7%).
`
`EDUCATION OF NEXT-GENERATION PHARMACEUTICAL SCIENTISTS
`
`My first academic position at the Ohio State University, where I trained 36 Ph.D. and 5 M.Sc. in
`pharmaceutical sciences, has led to my opinion that a new, cross-fertilization approach is needed to
`train drug development scientists who can translate the explosive growth in biomedical scientific
`knowledge into efficacious and cost-efficiently cancer treatments. This, in turn, requires bringing
`professors in diverse disciplines (biological, physical, computational sciences) to share the training
`of graduate students so that the future scientists will have the unique combination of expertise that
`has proven elusive thus far, in part due to the silo structures in academic programs. Hence, I took
`early retirement and left my tenured professor position in 2013 and became part-time, non-tenured
`professors at three different universities. This arrangement, albeit unorthodox, has provided the
`opportunity to pioneer this new educational approach. In September 2014, I initiated the first
`program at the University of Oklahoma Health Sciences Center, where we currently have nine pre-
`doctoral and three post-doctoral students (including a visiting student from Politecnico di Milano).
`
`
`
`
`
`
`CURRICULUM VITAE
`
`
`
`
`
`
`
`Jessie L.-S. Au
`U.S.A.
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`
`
`NAME:
`CITIZENSHIP:
`
`
`
`EDUCATION
`
`
`Degree
`Pharm.D.
`
`
`Ph.D.
`
`
`
`Year
`1972
`
`1980
`
`
`
`
`Institution
`
`School of Pharmacy
`University of California
`San Francisco, CA
`
`
`
`
`Dept. of Pharmaceutical Chemistry
`University of California
`
`San Francisco, CA
`
`
`
`
`
`
`
`Dept. of Experimental Therapeutics
`Roswell Park Memorial Institute
`
`Buffalo, NY
`
`
`
`
`
`1 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 2
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`HONORS AND AWARDS
`
`
`President Scholarship, 1971-1972; Edith Claypole-Joe Shoong Scholarship, 1976-1977; Patent Fund
`Award; NIH Predoctoral Fellow, 1977-1979, University of California San Francisco.
`Rho Chi National Graduate Scholarship, 1977-1978.
`Technology Transfer Award, International Union Against Cancer, 1981.
`New Investigator Research Award, NIH, 1982.
`Research Career Development Award, NIH, 1990.
`MERIT Award, NIH, 1992.
`University Distinguished Scholar Award, The Ohio State University, 1992.
`Dorothy M. Davis Chair of Cancer Research, The Ohio State University, 1992.
`Fellow, American Association of Pharmaceutical Scientists, 1992.
`Frank Duckworth Eminent Visiting Scholar, University of Florida, 1993.
`Joseph V. Swintosky Distinguished Lecturer, University of Kentucky, 1997.
`Distinguished University Professor, The Ohio State University, 1998.
`Fellow, American Association for the Advancement of Science, 1999.
`Distinguished Visiting Professor, National University of Singapore, 2000.
`Alumni Row, University of California San Francisco, 2000.
`Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism,
`American Association of Pharmaceutical Scientists, 2004.
`Semi-Finalist, Inaugural NIH Director’s Pioneer Award
`Member, FDA Pharmaceutical Sciences and Clinical Pharmacology Advisory Board, 2006-2010,
`2013-2016, 2016-2019
`Co-founder & Co-Chair, Bladder Cancer Research Network (Co-chair with Dr. Seth Lerner of Baylor
`Medical University, consortium of 30+ academic/research urologic oncologists)
`Member, Scientific Advisory Board, Bladder Cancer Advocacy Network, 2006-present
`Member, NCI Bladder Cancer Task Force, 2010-present
`Member, The Cancer Genome Atlas (TCGA) Bladder Cancer Working Group, 2010-present
`Profiled as Distinguished Pharmaceutical Scientist (12th in the series of a total of 28 spanning 1987
`through 2014), American Association of Pharmaceutical Sciences (about 10,000 members),
`2008
`Mosier Endowed Chair in Pharmaceutical Sciences, University of Oklahoma Health Sciences Center,
`2014-present
`Distinguished Scholar in Pharmacy, Chinese University of Hong Kong, 2015.
`Endowed Chair in Systems Pharmacology, Taipei Medical University, 2016
`
`MEMBERSHIP
`
`
`American Association of Cancer Research; American Association of Cancer Research Women in
`Cancer Research; American Association of Pharmaceutical Scientists; American Association for
`Advancement of Science
`
`
`
`PROFESSIONAL EXPERIENCE
`
`Clinical Pharmacist: Staff/Supervisor, Presbyterian Hospital of Pacific Medical Center, San
`Francisco, CA, 1972-1975; Volunteer pharmacist, Haight-Ashbury Free Medical Clinics, San
`Francisco, CA, 1977.
`
`
`
`2 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 3
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`Research Affiliate III, 1979-1980; Cancer Research Scientist I and II, Roswell Park Memorial
`Institute, Buffalo, NY, 1980-1983
`Assistant Professor, Division of Pharmaceutics and Pharmaceutical Chemistry, College of
` Pharmacy, The Ohio State University, 1983-1989
`Member, Cancer Pharmacology Program, Institute of Biomedical Sciences Academic Sinica,
` Taipei, Taiwan, 1988-1993.
`Associate Professor, Division of Pharmaceutics and Pharmaceutical Chemistry, College of
` pharmacy, The Ohio State University, 1989-1992.
`Acting Co-Director, Developmental Therapeutics Program, OSU Comprehensive Cancer Center,
`
`1991-1992.
`Professor, Colleges of Pharmacy and Medicine, The Ohio State University, 1992.
`Co-Director, Head and Neck Oncology Program, OSU Comprehensive Cancer Center, 1992-
` 1993.
`Co-Director, Urologic Oncology Program, OSU Comprehensive Cancer Center, 1992-1999.
`Director of Translational Research, OSU Comprehensive Cancer Center, 1993-1994.
`Deputy Director, OSU Comprehensive Cancer Center, 1994-1997.
`Dorothy M. Davis Chair in Cancer Research, The Ohio State University, 1992-2004.
`Member, OSU Comprehensive Cancer Center, 1983-2013.
`Distinguished University Professor, Colleges of Pharmacy, Medicine and Engineering, The Ohio
`State University, 1998-2013.
`Distinguished University Professor Emeritus, The Ohio State University, 2013-present.
`Adjunct Professor, Department of Surgery, Medical University of South Carolina, 2013-present.
`Adjunct Professor, Department of Pharmaceutical Sciences, University of Oklahoma, Oklahoma
`City, OK, 2013-2014
`Research Professor & Mosier Endowed Chair, Department of Pharmaceutical Sciences, University of
`Oklahoma, Oklahoma City, OK, 2014-present
`Co-Founder (2003) and Chief Scientific Officer (2013-present), Optimum Therapeutics LLC
`Visiting Professor (since 2014) and Chair Professor in Systems Pharmacology (since 2016), Taipei
`Medical University, Taipei, Taiwan
`Founding Director, Institute of Quantitative Systems Pharmacology, Carlsbad, CA, 2016.
`
`ADMINISTRATIVE EXPERIENCE
`
`Research administration:
` Experience in leading a relatively large research laboratory (40+ research personnel) and large-
`scale collaborative research projects in the U.S., Canada and Europe.
` As Chief Scientific Officer, responsible for working with US government funding agencies to
`establish and implement policies and procedures on ensuring research integrity
`
`Academic administration:
` Held various administration positions in the Ohio State University Comprehensive Cancer
`Center and appointments to university level committees including the budget restructuring
`committee (responsible for reviewing and making recommendations on revenue sources). As
`Deputy Director of the Comprehensive Cancer Center with 200+ members drawn from 11
`colleges, I was responsible for the preparation and defense of the NCI Cancer Center Core Grant
`and its expenditure, and budgeting and expending discretionary funds from the Cancer Hospital,
`the assignment of cancer center space (26,000 nsf), and the strategic and programmatic
`
`
`
`3 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 4
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`planning. I also worked on initiatives to promote and leverage technology transfer as an
`alternative source of revenues to support cancer research.
` Developed the first-of-its-kind graduate program in drug development. This program involves
`shared teaching of Ph.D. students by two or more professors in one or more institutions so that
`the student acquires diverse research expertise (vs. students in traditional programs who are
`typically trained in a single laboratory).
`
`
`PROFESSIONAL SERVICE (National and International)
`
`Participant in the International Cancer Research Technology Transfer Program sponsored by the
`
`International Union Against Cancer, 1982
`Reviewer for Cancer Research, Cancer Chemotherapy and Pharmacology, Analytical Biochemistry,
`Pharmaceutical Research, Journal of Pharmaceutical Sciences, In vitro, Journal of National
`Cancer Institute, Biopharmaceutics and Drug Disposition, Journal of Drug Targeting, Journal of
`Chromatography, Oncogene, Clinical Cancer Research, PharmSci, Journal of Controlled
`Release, Journal of Pharmacology and Experimental Therapeutics, Biochemical Pharmacology,
`Nature Biotechnology, Biomaterials, Journal of Controlled Release, AAPS J
`Member, NCI Program Project Grant Site Visit Team, 1983, 1992, 1993, 1998-2002, 2010
`Member, NIH Experimental Therapeutics II Study Section, 1987-1992; NIH Small
`Business Innovative Research Study Section, 1987-1990; NIH AIDS and Related Research
`Review Group, 1989; NIH Pediatric AIDS Clinical Trial Study Section, 1993; NIH Alternative
`Medicine Study Section, 1993; NIH Pharmacology Study Section, 1994-96; NIH Experimental
`Therapeutic II Study Section, 1997; NCI Manpower (Training Grants) Study Section, 1997; NCI
`Cancer Center Support Grant Review Committee, 1997, 1998, 2005; NIH Developmental
`Therapeutics Study Section, 2002-2005; NIH Biomaterials and Biointerfaces Study Section,
`since 2010; NCI Center of Cancer Nanotechnology Excellence, since 2010; Miscellaneous
`NCI/NIH Study Sections, 2007-present (see below for additional listing since 2009)
`Chair, Experimental Therapeutic II Special Study Section, 1996, 1997
`Member, U.S. Army Medical R & D Command Breast Cancer Research Program Review Group,
`
`1994, 1997
`Member, Oncology Boundary Advisory Committee, NIH, 2001-2003 (responsible for realignment of
`oncology-related study sections which took place in 2003)
`Member, NCI Scientific Review Group Translational and Clinical Subcommittee D, 2001 – 2003.
`Member, Katholieke Universiteit Leuven, Research Grant Application Evaluation Committee, 2002;
`Reviewer, Research grants for Fonds zur Forderung, Der Weissenchaftsfonds. Austria, 2004
`Member, Arizona Disease Control Research Commission Review Panel, 1997-2002
`Ad hoc Member, Board of Scientific Counselors, National Center for Research Resources, Review of
`Biomedical Engineering and Instrumentation Program, 1996
`Chairperson, AAPS Annual Meeting Symposia, 1992, 2001
`Member, Editorial Advisory Board, Pharmaceutical Research, 1990-mid 2000s
`Member, Editorial Advisory Board, AAPS Journal, 1998-mid 2000s
`Member, American Association of College of Pharmacy Graduate Affairs Committee, 1992 and 1993
`Chair (1993-1994) & Member (1994-1995), American Association of College of Pharmacy Paul
`
`Dawson Biotechnology Award Committee
`Member, American Association of Pharmaceutical Scientists: Task Force on Alternative Sources of
`Revenue, 1995-1996; Bylaw Committee, 1995-1997
`Member, NCI Strategy Planning Meeting on Intraperitoneal Cisplatin and Paclitaxel in ovarian
`
`
`
`4 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 5
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`Cancer, 1995
`
`External Reviewer of academic programs and faculty, University of Utah, University of Georgia,
`University of Michigan, University of Alabama, SUNY Stony Brook, University of Singapore,
`National Health Research Institute (Taiwan)
`Scientific Advisor, University of Pittsburgh Cancer Institute, 1997-1998; Roswell Park Cancer
`Institute, 1998-2001
`Member, American Association of Cancer Research Program Committee, 1997, 1998, 2001.
`Scientific Advisory Board, National Cancer Institute/Controlled Release Society International
`Symposium on Tumor Targeted Delivery Systems, 2000
`Member, NCI Gynecologic Oncology Group Retreat, May, 2000
`Member, NCI State of the Science Meeting on Lung Cancer, June, 2000
`Member, NCI State of the Science Meeting on Bladder Cancer, September, 2000
`Member, Scientific Program Committee, EORTC-NCI-AACR 2002 Symposium on Molecular
`Targets and Cancer Therapeutics, Frankfurt, Germany, 2002
`Chairperson, Electorate Nominating Committee, Pharmaceutical Sciences, American Association for
`the Advancement of Science (AAAS), 2001-2002
`Member-at-Large, AAAS Pharmaceutical Section, 2003–2006
`Member, Program Committee, Co-Chair on Symposium on Growth factor receptors and beyond.
`Second Pharmaceutical Sciences World Congress, Kyoto, Japan, 2004.
`Member and Co-Chair, External Advisory Committee, Oklahoma Biomedical Research Infrastructure
`Network (BRIN) Program IdeA Networks for Biomedical Research Excellence (INBRE), 2004-
`2019 (Co-Chair since 2014).
`Reviewer, Cancer Research UK, 2004, 2005
`Chair, AAPS PPDM Hot Topics Committee (FDA Critical Path), 2004, 2005
`Member, Scientific Advisory Board, Attenuon LLC, 2004-2009
`Review Committee, Science Foundation Ireland, 2006
`Member, Board of Consulting Editors, Pharmaceutical Research, 2006-2008
`Member, Program Committee; Convener, Symposium on Molecular Targeting in Cancer
`Chemotherapy, Third Pharmaceutical Sciences World Congress, Amsterdam, Netherlands, 2007
`Member, Scientific Advisory Board, Ascent Biomedical Ventures 2004-2007
`Co-Chair, Bladder Cancer Research Network (Co-Chair with Seth Lerner of Baylor Medical
`University, a newly formed group of 40+ academic/research urologic surgeons), 2007-present
`Member, Scientific Advisory Board & Management Committed, Bladder Cancer Advocacy Network,
`2010-present
`Member, Bladder Cancer Think Tank Steering Committee, 2007-present
`Member, NCI Bladder Cancer Task Force, 2010-present
`Member, The Cancer Genome Atlas (TCGA) Bladder Cancer Working Group, 2010-present.
`Member, Editorial Board, Current Cancer Drug Targets, 2013-present
`Recent NIH/NCI review activities, since 2009
` ZHD1-DSR-K-(09), Biological Testing Facility, February 9, 2009
` ZCA1-RTRB-2-(R1), February 24, 2009
` ZCA1-RTRB-2-(C1), NCI Small Business Innovation Research (SBIR) Program Topic
`229 - Development of Molecular Pharmacodynamic Assays for Targeted Therapies,
`March 19, 2009
` ZCA1-RPRB-M-(F3), July 20, 2009
` ZCA1-RPRB-J-(09), NCI Grant Opportunity Clinical/Translational, August 5-6, 2009
` ZCA1-GRB-S-(M1), January 22, 2010
` BMBI Biomaterials and Biointerfaces, February 3-4, 2010
`
`
`
`5 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 6
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
` ZCA1-GRB-P-(M1) and ZCA1-GRB-S-(M2), Centers of Cancer Nanotechnology
`Excellence, February 24-26, 2010
` ZCA1-RPRB-O-(M1), Cellular and Tissue Oncology PO1, March 1-3, 2010
` ZCA1-PCRB-B-(A1), NCI Loan Repayment Program, May 17, 2010
` BMBI Biomaterials and Biointerfaces, May 25-26, 2010
` ZCA1 RPRB-0 (J1) Basic, Translational and Clinical Oncology PO1, September 28-29,
`2010
` ZCA1 RPRB-M (J1) Cellular & Tissue Biology II P01, October 19, 2010
` ZRG1 OTC-H (14) B Small Business: Cancer Diagnostics and Treatments (CDT), July
`14-15, 2011
` ZRG1 BST-N (90) Bioengineering Sciences and Technologies R15, October 26, 2011
` ZRG1 BST-M (02) Bioengineering Sciences and Technologies, February 9-10, 2012
` ZRG1 OTC-H (13), Cancer Diagnostic and Treatment (CDT) SBIR/STTR, March 5-6,
`2012
` ZDK1-GRB-S (01), NIDDK, April 5, 2012
` ZRG1-OTC-X (90), Cancer Therapeutics R15, May 24, 2012
` ZDK1-GRB-S (J1), NIDDK, September 4, 2012
` ZCA1-PCRB-B-(A1), NCI Loan Repayment Program, May 8, 2013
` ZRG1-OTC-X (90), Cancer Therapeutics R15, May 22, 2013
` ZEB1-OSR-F (01), NIBIB Conference Grant, July 9, 2013
` ZDK1-GRB-S-J1, NIDDK, August 16, 2013
` ZRG1-OTC-H-13, CSR, November 4, 2013
` ZCA1-PCRB-B-(A1), NCI Loan Repayment Program, April, 2014
` BMBI Biomaterials & Biointerfaces Study Section, February 4-5, 2015
` ZCA1-TCRB-9-(M1), NCI, Innovative Research in Cancer Nanotechnology, March 19,
`2015
` ZCA1 TCRB-9 (O1) R, NCI, Innovative Research in Cancer Nanotechnology, July 13,
`2015
` BMBI Biomaterials and Biointerfaces, February 11-12, 2016
` ZTR1 DPI-2 (01), NCATS, Pre-clinical Research Based on Existing repurposing Tools,
`May 18-19, 2016
`Member, American Association of Cancer Research Colon Cancer Research Fellowships Scientific
`Review Committee, 2014, 2015
`Member, Grant Review Committees, Bladder Cancer Advocacy Network, 2009-present
`Member, FDA Pharmaceutical Science Advisory Committee, 2006-2010, 2013-2016, 2016-2019
`Member, Biomaterials and Biointerfaces Study Section, NIH, 2016-2022
`Member, American Urologic Association Committee on Guidelines for diagnosis and treatment of
`non-metastatic muscle-invasive bladder cancer, 2016-2017.
`Chair, Symposium on Quantitative Systems Pharmacology: Application to cancer drug development
`and personalized/precision medicine, American Society of Pharmacology and Experimental
`Therapeutics Annual Meeting at Experimental Biology, 2017.
`
`
`ADMINISTRATIVE SERVICE: COLLEGE AND UNIVERSITY COMMITTEES
`
`Ohio State University
`Member, Pharmacy College Curriculum subcommittee, 1985-1988
`Member, Pharmacy College Admissions Committee, 1985-1988
`
`
`
`6 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 7
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`Member, Pharmacy College Honors and Undergraduate Research Committee, 1985-1988
`Faculty Advisor to the Pharmacy Kappa Epsilon Sorority, 1986-1989
`Member, Pharmacy College Affirmative Action Committee, 1989-1990
`Member/Chair, Search Committees for 4 faculty positions in Pharmaceutics Division, 1988-1990,
`1993-94
`Counselor, American Association of Colleges of Pharmacy Minority Research Program, 1989-1991
`Chair, Pharmacy Honors Committee, 1996-1997
`Member, Graduate and Research Committee, College of Pharmacy, 1984-1985, 1989-1999.
`Member, Search Committee for Associate Dean, 1998-2000
`Member, Pharmacy College Investigation Committee, 1999-present
`Member, Search Committee for Director of Drug Delivery, 1999-2001
`Reviewer for University Interdisciplinary Research Grants and American Cancer Society Starter
`
`Grants, 1989-1994
`Member, University Task Force to Address the Needs of Asian American Students, 1991-1993
`Member, University Distinguished Scholar Award Selection Committee, 1992-1994
`Member, Asian American Oversight Committee, 1993-1995
`Alternate Member, Research and Graduate Council, 1993-1995
`Member, Health Sciences Research Advisory Committee, 1994-1995
`Alternate Member, Faculty Council, 1995-1997
`Member, Provost’s Advisory Committee, 1994-1997
`Member, Provost’s Council on International Affairs, 1994-1996
`Member, Distinguished University Professor Selection Committee, 1996, 2000
`Member, Academic Enrichment Program Selection Committee, 1996, 1997
`Alternate Member, University Senate, 1991-1994, 1995-1997
`Ad Hoc Member, Industry and Technology Council of Central Ohio Leadership Committee, 1994-97
`Member, Council on Academic Excellence for Women, 1995-1998
`Member, University Central Budget Allocation Committee, 1996-1998
`Member, Oversight Committee for International Affairs, 1996-1999
`Member, President and Provost Advisory Council, OSU, 1998 (lifetime appointment)
`Member, Scientific Advisory Committee, NSF Mathematical Bioscience Institute, 2000-2005
`Member or Chair, Selection Committee for Distinguished University Professors and Distinguished
`University Lecturer, 1996, 1997, 2000, 2002, 2003, 2009
`
`
`Ohio State University Comprehensive Cancer Center (CCC)
`Member, Search Committee for Director of Developmental Therapeutics Program of OSU
`
`Comprehensive Cancer Center, 1990-1992
`Member, CCC/CHRI Strategic Planning Committee, 1992-1994
`Member, CCC/CHRI Space Committee, 1992-1994
`Chair, CCC Translational Research Committee, 1994-1997
`Chair, CCC/CHRI Space Committee, 1994-1997
`Chair, CCC/CHRI Shared Services Directors, 1994-1997
`Chair, CCC Block Award Committee, 1994-1997
`Chair, CCC/CHRI Drug Development Group, 1995-1997
`Chair, American Cancer Society Institutional Grant Committee, 1995-1997
`Chair, CCC/CHRI Development Grant Committee, 1995-1997
`Member, CCC/CHRI Disease Specific Committee, 1992-1997
`Member, CCC/CHRI Basic Science Committee, 1993-1997
`Member, CCC/CHRI Executive Committee, 1994-1997
`
`
`7 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 8
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`Member, CCC Human Cancer Genetics Search Committee, 1994-1997
`Member, CCC/CHRI Institutional Biosafety/Etiologic Agents Committee, 1994-1997
`Member, Office of Health Services Space Committee, 1994-1997
`Member, The Interdisciplinary Research Center Directors Forum, 1994-1997
`Member, CCC Program Directors Committee, 1994-1997
`Co-Director, Drug Development Service, 1996-1998
`
`University of Oklahoma Health Sciences Campus
`Founder, Quantitative Systems Pharmacology track in Pharmaceutical Sciences Ph.D. program, 2014
`Member, Faculty Search Committee, 2015-2016
`
`
`
`8 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 9
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`PUBLICATIONS
`
`A. Peer-reviewed papers (including reviews)
`
`1. Wu, A.T., Au, J.L.-S., and Sadee, W. Hydroxylated metabolites of R,S-1-(tetrahydro-2-furanyl)-
`5-fluorouracil in rats and rabbits. Cancer Res., 38:210-214, 1978.
`
`
`2. Au, J.L.-S., Wu, A.T., Friedman, M.A., and Sadee W. Pharmacokinetics and metabolism of
`ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil) in man. Cancer Treat. Rep., 63:343-350,
`1979.
`
`
`3. Au, J.L.-S. and Sadee W. 5-Fluorouracil concentrations in human plasma following R,S-1-
`(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration. Cancer Res., 39:4289-4290,
`1979.
`
`
`4. Au, J.L.-S. and Sadee W. Activation of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil) to
`fluorouracil and -butyrolactone. Cancer Res., 40:2814-2819, 1980.
`
`
`5. Au, J.L.-S. and Sadee, W. Stereoselective metabolism of ftorafur (R,S-(1-tetrahydro-s-furanyl)-
`5-fluorouracil). Cancer Chemotherap. Pharmacol., 7:55-59, 1981.
`
`
`6. Au, J.L.-S., Wientjes, M.G., Luccioni, C., and Rustum, Y.M. Reversed phase ion-pair high
`pressure liquid chromatographic assay of 5-fluorouracil, 5'-deoxy-f-fluorouridine, their
`nucleosides, mono-,di-, and triphosphate nucleotides with a mixture of quaternary ammonium
`ions. J. Chromatogr., 228:245-256, 1982.
`
`
`7. Au, J.L.-S., Rustum, Y.M., Mittelman, A., Ledesma, E., and Creaven, P.J. Clinical
`pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in the treatment
`of colorectal adenocarcinoma. Cancer Res., 42:2930-2937, 1982.
`
`
`8. Rustum, Y.M., Danhauser, L.L., Luccioni, C., and Au, J.L.-S. Determinants of response to
`antimetabolites and their modulation by normal purine and pyrimidine metabolites. Cancer
`Treat. Rep., 65 (Supp. 3):73-82, 1982.
`
`
`9. Au, J.L.-S., Rustum, Y.M., Minowada, J., and Srivastava, B.I.S. Differential selectivity of 5-
`fluorouracil and 5'-deoxy- 5-fluorouridine in cultured human B lymphocytes and mouse L1210
`leukemia. Biochem. Pharmacol., 32:541-546, 1983.
`
`
`
`10. Au, J.L.-S., Walker, J.S., and Rustum, Y.M. Pharmacokinetic studies of 5-fluorouracil and 5'-
`deoxy-5-fluorouridine in rats. J. Pharmacol. Exper. Therap., 227:174-180, 1983.
`
`
`11. Steinberg, A., Petrelli, N.J., Mittelman, A., Rustum, Y.M., Au, J.L.-S., and Creaven, P. A
`combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma. Cancer
`Chemotherap. Pharmacol., 13:218-222, 1984.
`
`
`12. Au, J.L.-S. Effect of age on the disposition and tissue clearances of 5-fluorouracil and 5'-deoxy-
`5-fluorouridine. Pharm. Res., 6:279-284, 1985.
`
`
`
`9 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 10
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`13. Trave, F., Cannobio, L., Au, J.L.-S., and Rustum, Y.M. Role of administration on the
`therapeutic efficacy of 5-fluorouracil and 5'-deoxy-5-fluorouridine. J. Natl. Cancer Inst.,
`78:527-532, 1987.
`
`
`14. Au, J.L.-S., Su, M-H., and Wientjes, M.G. Isocratic ion-pair reversed-phase high performance
`liquid chromatographic analysis of adenylate nucleotides. J. Chromatogr., 423:308-312, 1987.
`
`
`15. Au, J.L.-S. Disposition and availability of the 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine
`after oral administration in rats. J. Pharm. Sci., 76:699-702, 1987.
`
`
`16. Wientjes, M.G. and Au, J.L.-S. Inhibition of intestinal pyrimidine nucleoside phosphorylases.
`Pharm. Res., 4:425-428, 1987.
`
`
`17. Au, J.L.-S., Rustum, Y.M., and Slocum, H.K. Biological activities of 5-fluorouracil and its
`prodrug 5'-deoxy-5-fluorouridine in rats. Cancer Drug Delivery, 4:137-144, 1987.
`
`18. Au, J.L.-S., Bramer, S.L., and Wientjes, M.G. Effect of uridine coadministration on
`5'-deoxy-5-fluorouridine disposition in rats. Cancer Chemother. Pharmacol., 22:5-10, 1988.
`
`
`19. Bramer, S.L., Gunnarsson, L., and Au, J.L.-S. Biologic activity of 5'-deoxy- 5-fluorouridine by
`rectal administration. Pharm. Res., 6:318-322, 1989.
`
`
`20. Au, J.L.-S. and Gunnarsson, L. Absorption of 5'-deoxy-5-fluorouridine from colon. Pharm.
`Res., 6:323-327, 1989.
`
`
`21. Au, J.L.-S., Su, M-H., and Wientjes, M.G. Acetonitrile extraction of intracellular nucleosides
`and nucleotides. Clin. Chem., 35:48-51, 1989.
`
`22. Dalton, J.T., Geuns, E., and Au, J.L.-S. High performance liquid chromatographic analysis of
`mitomycin C in rat and human plasma and urine. J. Chromatogr., 495:330-337, 1989.
`
`
`23. Schmittgen, T.D., Au, J.L.-S., Wientjes, M.G., Badalament, R.A., and Drago, J.R. Cultured
`human bladder tumors for pharmacodynamic studies. J. Urol., 145:203-207, 1991.
`
`
`24. Wientjes, M.G., Dalton, J.T., Badalament, R.A., Drago, J.R., Dasani, B.M., and Au, J.L.-S. A
`method to study drug concentration-depth profiles in tissues: Mitomycin C in dog bladder wall.
`Pharm. Res., 8:168-173, 1991.
`
`
`25. Au, J.L.-S., Dalton, J.T., and Wientjes, M.G. Evidence of significant absorption of sodium
`salicylate from urinary bladders of rats. J. Pharmacol. Exper. Therap., 258:357-364, 1991.
`
`
`26. Wientjes, M.G. and Au, J.L.-S. High performance liquid chromatographic analysis of
`2',3'-dideoxyinosine in biological samples. J. Chromatogr., 563:400-406, 1991.
`
`
`27. Schmittgen, T.D., Wientjes, M.G., Badalament, R.A., and Au, J.L.-S. Pharmacodynamics of
`mitomycin C in cultured human bladder tumors. Cancer Res., 51:3849-3856, 1991.
`
`
`
`
`
`
`
`
`10 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 11
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`
`28. Wientjes, M.G., Dalton, J.T., Badalament, R.A., Drago, J.R., and Au, J.L.-S. Bladder wall
`penetration of intravesical mitomycin C in dogs. Cancer Res., 51:4347-4354, 1991.
`
`
`29. Dalton, J.T., Wientjes, M.G., Badalament, R.A., Drago, J.R., and Au, J.L.-S. Pharmacokinetics
`of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res., 51:5144-5152,
`1991.
`
`
`30. Dalton, J.T., Harrington, M., and Au, J.L.-S. Evidence of significant absorption of antipyrine
`from urinary bladders of rats. J. Pharmacol. Exper. Therap., 260:608-613, 1992.
`
`
`31. Schmittgen, T.D., Koolemans-Beynen, A., Webb, T.E., Rosol, T.J., and Au, J.L.-S. Effects of
`5-fluorouracil, leucovorin and glucurate in rat colon tumor explants. Cancer Chemother.
`Pharmacol., 30:25-30, 1992.
`
`
`32. Wientjes, M.G. and Au, J.L.-S. Pharmacokinetics of oral 2',3'-dideoxyinosine in rats. Pharm.
`Res., 9:822-825, 1992.
`
`33. Wientjes, M.G. and Au, J.L.-S. Lack of pharmacokinetic interaction between 2',3'-
`dideoxyinosine and 3'-azido-3'-deoxythymidine in rats. Antimicrob. Agents Chemother.,
`36:665-668, 1992.
`
`
`34. Wientjes, M.G., Mukherji, E.M., and Au, J.L.-S. Nonlinear disposition of intravenous 2',3'-
`dideoxyinosine in rats. Pharm. Res., 9:1070-1075, 1992.
`
`
`35. Bramer, S.L., Wientjes, M.G., and Au, J.L.-S. Absorption of 2',3'-dideoxyinosine from lower
`gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and
`rectum. Pharm. Res., 10:763-770, 1993.
`
`
`36. Bramer, S.L., Wientjes, M.G., and Au, J.L.-S. Gastrointestinal and hepatic first pass elimination
`of 2',3'-dideoxyinosine in rats. J. Pharmacol. Exper. Therap., 265:731-738, 1993.
`
`37. Dalton, J.T. and Au, J.L.-S. 2',3'-dideoxyinosine is not metabolized in human placenta. Drug
`Metab. Disp., 21:544-546, 1993.
`
`
`38. Wientjes, M.G., Badalament, R.A., Wang, R.C., Hassan, F., and Au, J.L.-S. Penetration of
`mitomycin C in human bladder. Cancer Res., 53:3314-3320, 1993.
`
`
`39. Wientjes, M.G., Badalament, R.A., and Au, J.L.-S. Use of pharmacologic data and computer
`simulations to design an efficacy trial of intravesical treatment for superficial bladder cancer.
`Cancer Chemother. Pharmacol., 32:255-262, 1993.
`
`
`40. Au, J.L.-S., Wientjes, M.G., Rosol, T.J., Koolemans-Beynen, A., Goebel, E.A., and Schuller,
`D.E. Histocultures of patient head and neck tumors for pharmacodynamic studies. Pharm. Res.,
`10:1493-1499, 1993.
`
`
`
`
`
`
`
`
`
`11 of 68
`
`Alkermes, Ex. 1005
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`10/11/2016
`Page 12
`
`Au, Jessie L.-S.
`Curriculum Vitae
`
`
`
`41. Yeh, T.-K., Dalton, J.T., and Au, J.L.-S. High performance liquid chromatographic
`determination of pentamidine in plasma. J. Chromatogr., 622:255-261, 1993.
`
`42. Schmittgen, T.D., Weaver, J.M., Badalament, R.A., Wientjes, M.G., Klein, E., Young, D., and
`Au, J.L.-S. Correlation of human bladder tumor histoculture proliferation and sensitivity to
`mitomycin C with tumor pathobiology. J. Urol., 152:1632-1636, 1994.
`
`
`43. Mukherji, E., Millenbaugh, N., and Au, J.L.-S. Percutaneous absorption of 2',3'-dideoxyinosine
`in rats. Pharm. Res., 11:809-815, 1994.
`
`
`44. Chai, M.-F., Wientjes, M.G., Badalament, R.A., Burgers, J.K., and Au, J.L.-S.
`Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J. Urol.,
`152:374-378, 1994.
`
`
`45. Mukherji, E., Au, J.L.-S., and Mathes, L.E. Differential antiviral activity and intracellular
`metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob.
`Agents Chemother., 38:1573-1579, 1994.
`
`
`46. Kang, H.-J.K., Wientjes, M.G., and Au, J.L.-S. Tissue pharmacokinetics of 2',3'-dideoxyinosine
`in rats. Biochem. Pharmacol., 48:2109-2116, 1994.
`
`
`47. Dalton, J.T., Wientjes, M.G., and Au, J.L.-S. Effect of bladder resorption on pharmacokinetic
`data analysis. J. Pharmacokin. Biopharm., 22:183-205, 1994.
`
`48. Gao, X., Buffington, C.A., and Au, J.L.-S. Effect of interstitial cystitis on drug absorption from
`urinary bladder. J. Pharmacol. Exper. Therap., 271:818-823, 1994.
`
`
`49. Au, J.L.-S. Integrated pharmacokinetic and pharmacodynamic studies to improve intravesical
`treatment of bladder cancer. Cancer Bulletin, 46:48-57, 1994.
`
`
`50. Gupta, E., Wientjes, M.G., and Au, J.L.-S. Penetration kinetics of 2',3'-dideoxyinosine in
`dermis is described by the distributed model. Pharm. Res., 12:108-112, 1995.
`
`
`51. Wientjes, M.G., Pretlow, T.G., Badalament, R.A., Burgers, J.K., and Au, J.L.-S. Histocultures
`of human prostate tissues for pharmacologic evaluation. J. Urol., 153:1299-1302, 1995.
`
`
`52. Song, D. and Au, J.L.-S. Isocratic high performance liquid chromatographic assay of taxol in
`biological fluids and tissues using automated column switching.